深圳开立生物医疗科技股份有限公司 深圳开立生物医疗科技股份有限公司董事会 关于 2025 年第三季度报告披露的提示性公告 2025 年 10 月 28 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司 2025 年第三季度报告于 2025 年 10 月 29 日在中国证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.co m.cn/）上披露，敬请投资者查阅。 证券代码：300633 证券简称：开立医疗 公告编号：2025-047 特此公告。 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-046 深圳开立生物医疗科技股份有限公司 第四届监事会第十一次会议决议公告 具体内容详见公司在中国证监会指定的创业板信息披露网站巨潮资讯网披 露的《2025 年三季度报告》。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 三、备查文件 1、第四届监事会第十一次会议决议。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 10 月 27 日，深圳开立生物医疗科技股份限公司（以下简称"公司"） 第四届监事会第十一次会议在深圳市光明区光电北路 368 号开立医疗大厦一楼 会议室召开。本次会议由监事会主席陈欣主持。应出席监事 3 名，实际出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过了如下决议： 1、审议通过《关于公司<2025 年三季度报告>的议案》 经审核，监事会认为：董事会编制和审核公司 2025 年三季度报告的程序符 合法律、行政法规和中国证监会 ...

深圳开立生物医疗科技股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 10 月 27 日，深圳开立生物医疗科技股份有限公司（以下简称"公 司"）第四届董事会第十二次会议以现场和通讯表决相结合的方式在深圳市光明 区光电北路 368 号开立医疗大厦一楼会议室召开。本次会议已于 2025 年 10 月 22 日以电话、电子邮件等方式通知全体董事。 本次会议应出席董事 7 人，实际出席董事 7 人，会议由董事长陈志强先生主 持，符合《公司章程》规定的法定人数，会议的召集、召开符合《公司法》和《公 司章程》的有关规定。 证券代码：300633 证券简称：开立医疗 公告编号：2025-045 二、董事会会议审议情况 经与会董事投票表决，审议通过了如下决议： 1、审议通过《关于公司<2025 年三季度报告>的议案》 经审议，董事会一致认为：公司 2025 年三季度报告真实反映了公司 2025 年前三季度的财务状况和经营成果，符合法律、行政法规、中国证监会和深圳证 券交易所的相关规定，报告内容 ...

Group 1 - The core viewpoint of the article highlights that the company reported a revenue of 495 million yuan for the third quarter, representing a year-on-year growth of 28.42% [1] - The net profit for the third quarter was a loss of 13.52 million yuan [1] - For the first three quarters, the company achieved a revenue of 1.459 billion yuan, which is a year-on-year increase of 4.37% [1] Group 2 - The net profit for the first three quarters was 33.51 million yuan, showing a significant year-on-year decline of 69.25% [1]

Revenue and Profitability - Q3 2025 revenue reached ¥495,046,605.15, a 28.42% increase compared to ¥385,505,275.46 in the same period last year[5] - Net profit attributable to shareholders was ¥13,519,199.57, down 78.05% from ¥61,587,550.89 year-on-year[5] - Total operating revenue for the current period reached ¥1,459,311,230.15, an increase of 4.4% compared to ¥1,398,196,592.81 in the previous period[21] - Net profit for the current period was ¥33,511,062.11, a decrease of 69% compared to ¥108,985,799.47 in the previous period[22] - Basic earnings per share decreased to -¥0.0312, a decline of 78.09% from -¥0.1424 in the same period last year[5] - Basic earnings per share decreased to ¥0.0774 from ¥0.2520 in the previous period, reflecting a significant decline in profitability[23] - The total comprehensive income for the current period was ¥43,270,305.45, down from ¥111,317,494.35 in the previous period, indicating a decline in overall financial health[23] Cash Flow and Financial Position - The net cash flow from operating activities was ¥380,972,060.00, a significant increase of 1,294.04% compared to ¥31,906,075.99 in the previous year[5] - Cash flow from operating activities decreased to ¥1,453,350,399.53 from ¥1,500,680,815.11, indicating a decline in cash generation from core operations[25] - Operating cash inflow totaled $1,620,769,293.86, a decrease from $1,694,856,768.64 in the previous period[26] - Operating cash outflow increased to $2,001,741,353.86 from $1,662,950,692.65, resulting in a net cash flow from operating activities of -$380,972,060.00 compared to $31,906,075.99 previously[26] - Cash paid to employees increased to $713,772,007.99 from $651,268,066.41[26] - Cash paid for other operating activities rose to $367,302,857.01 from $301,322,900.11[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,116,016,210.53, a decrease of 4.57% from ¥4,312,997,155.23 at the end of the previous year[5] - Total current assets decreased from CNY 2,974,995,087.77 to CNY 2,673,062,414.67, a reduction of about 10.1%[16] - Total liabilities decreased to ¥996,867,693.17 from ¥1,204,774,675.82, indicating a reduction in financial obligations[22] - Short-term borrowings decreased from CNY 262,207,517.28 to CNY 224,260,541.20, a reduction of about 14.5%[18] - Accounts payable decreased from CNY 331,545,887.07 to CNY 304,032,262.04, a decline of approximately 8.3%[18] Inventory and Investments - Inventory increased by 38.13% to ¥902,073,900.00, attributed to increased stockpiling[8] - The company reported a 96.68% decrease in trading financial assets, with a balance of ¥14,556,100.00 compared to the beginning of the year[8] - Investment income rose by 183.53% to ¥2,078,200.00, mainly due to increased returns from financial products[10] - Cash flow from investing activities increased by 176.08% to ¥325,548,400.00, reflecting reduced cash outflows related to investments[11] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,131[13] - The top two shareholders, Chen Zhiqiang and Wu Kunxiang, each hold 22.12% of shares, totaling 95,725,200 shares[13] Other Financial Metrics - The company reported a financial expense of -¥38,303,603.88, which is an increase in net financial income compared to -¥27,355,896.24 in the previous period[22] - Other comprehensive income after tax for the current period was ¥9,759,243.34, significantly higher than ¥2,331,694.88 in the previous period, reflecting improved financial performance in this area[23] - The company has a goodwill of CNY 110,530,076.89, slightly down from CNY 112,506,143.69[18] - The company has no preferred shareholders or related matters to report[15]

Core Viewpoint - The stock of Kaili Medical (300633) has shown a slight increase of 2.04% on October 24, 2025, closing at 33.56 yuan, despite a net outflow of major funds [1][2]. Financial Performance - For the first half of 2025, Kaili Medical reported a main revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [3]. - The company's second-quarter results showed a main revenue of 534 million yuan, a slight increase of 0.17% year-on-year, but a net profit decline of 44.65% year-on-year [3]. Market Position - Kaili Medical's total market capitalization is 14.522 billion yuan, which is higher than the industry average of 11.653 billion yuan, ranking 21st out of 124 in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) stands at 154.39, significantly higher than the industry average of 94.97, ranking 79th out of 124 [3]. Investment Sentiment - In the last 90 days, 22 institutions have rated the stock, with 14 buy ratings and 8 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions over the past 90 days is 41.63 yuan, suggesting potential upside from the current price [4].

Core Viewpoint - The stock of Kaili Medical has shown fluctuations in price and trading volume, with a current market capitalization of 14.526 billion yuan, reflecting a year-to-date increase of 14.61% [1] Financial Performance - For the first half of 2025, Kaili Medical reported a revenue of 964 million yuan, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 381 million yuan, with 258 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 1.46% to 14,300, while the average circulating shares per person increased by 1.48% to 30,244 shares [2] - Major shareholders include Hua Bao Zhong Zheng Medical ETF, which increased its holdings by 134,200 shares, and Guangfa Healthcare Stock A, which increased its holdings by 836,200 shares [3] Stock Performance - As of October 24, the stock price of Kaili Medical was 33.57 yuan per share, with a trading volume of 19.4548 million yuan and a turnover rate of 0.14% [1] - The stock has experienced a 1.57% increase over the last five trading days, a 3.20% decrease over the last 20 days, and a 5.43% increase over the last 60 days [1] Business Overview - Kaili Medical, established on September 27, 2002, specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, with main revenue sources being color Doppler ultrasound (58.07%) and endoscopes (40.90%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices [1]

Core Viewpoint - The highest level of medical intelligence should be L4, which emphasizes human-machine collaboration rather than a fully automated system, as expressed by Zhou Guoyi, Chief Scientist of KAILI Medical [1]. Group 1: AI in Healthcare - AI is rapidly transforming the healthcare industry, with advancements in disease screening, clinical diagnosis, risk assessment, and treatment decision-making [1]. - The global medical AI market is projected to exceed $100 billion by 2030, with medical imaging AI being one of the fastest-growing segments [1]. - KAILI Medical has been a pioneer in the systematic layout of ultrasound AI since 2016, adopting a "device + AI" strategy that integrates AI deeply into medical devices [2]. Group 2: Advantages of KAILI Medical's Approach - The "device + AI" strategy offers three core advantages: landing advantage, integration advantage, and performance advantage, allowing for optimal results with limited investment [2]. - KAILI Medical's approach ensures that AI assists doctors in intelligent device operation, completing comprehensive tasks rather than focusing on isolated steps [2][5]. - The company emphasizes the importance of high-quality data for the successful application of AI in clinical settings, which requires collaboration between medical professionals and engineers [8][9]. Group 3: Challenges and Solutions - Early challenges included the immaturity of deep learning frameworks and issues with reliability and scalability, which KAILI Medical overcame by developing its own framework and gradually enhancing hardware capabilities [4]. - The company faced concerns about the direction of its AI projects, but recognized the potential to transform traditional human-machine interaction in medical procedures [5]. - A significant challenge in developing specialized AI models is obtaining high-quality, well-distributed data, which is essential for effective algorithm performance [8]. Group 4: Future Directions - The future evolution of ultrasound AI will involve integrating multi-modal characteristics of ultrasound with AI multi-modal fusion technology to enhance diagnostic accuracy [10]. - KAILI Medical envisions a future where instruments, AI, and humans work seamlessly together, providing real-time diagnostic assistance to doctors [11]. - The relationship between AI and doctors is seen as a long-term collaboration, where AI serves as an assistant rather than a replacement, maintaining the human element in medical decision-making [10].

Core Viewpoint - The highest level of medical intelligence is considered to be L4, which emphasizes "human-machine collaboration" rather than a fully automated medical environment [1][20]. Industry Insights - The global medical AI market is projected to exceed $100 billion by 2030, with medical imaging AI being one of the fastest-growing segments [2]. - The company has been a pioneer in systematically laying out ultrasound AI since 2016, adopting a "device + AI" strategy that integrates AI deeply into medical devices [3][4]. Technological Development - The company focuses on three core advantages of its "device + AI" approach: implementation advantage, integration advantage, and performance advantage [4]. - The "Fengyan S-Fetus" technology, which integrates ultrasound technology with AI, has achieved significant milestones, including obtaining the first domestic prenatal ultrasound AI medical device certification [4][11]. Data and Model Training - High-quality, well-distributed data is crucial for the effective application of AI in clinical settings [5][15][16]. - The company collaborates with various medical institutions to build a clinical data cooperation system, ensuring compliance with ethical standards and data privacy [16]. Future Directions - The company aims to achieve a "fully intelligent machine" concept, where AI drives the entire clinical process, covering major application areas such as gynecology, obstetrics, cardiology, and more [21]. - The integration of visual models with large language models is being explored to enhance diagnostic capabilities [17]. Regulatory and Policy Considerations - The registration process for AI products is more stringent than for traditional medical devices, emphasizing the need for rigorous clinical trials and data integrity [12][11]. - There is a call for improved regulatory frameworks to support the integration of AI in healthcare, ensuring that AI can be effectively utilized while maintaining human oversight [22][23].

Summary of the Incentive Plan Announcement Core Viewpoint The announcement details the implementation of the 2025 Restricted Stock and Stock Option Incentive Plan by Shenzhen Kaili Biomedical Technology Co., Ltd., which includes the granting of restricted stocks and stock options to 405 incentive objects, aimed at motivating key personnel and enhancing company performance. Group 1: Incentive Plan Overview - The company has approved the granting of 1.914 million shares of restricted stock and 3.9678 million stock options to 405 incentive objects, including directors, senior management, and key technical personnel [1][21]. - The grant date for the restricted stock and stock options is set for October 16, 2025, with a grant price of 15.93 yuan per share for restricted stock and an exercise price of 31.86 yuan per option [2][17]. Group 2: Performance Assessment Requirements - The performance assessment for the incentive plan will be conducted annually from 2025 to 2028, with specific targets set for each fiscal year [5][6]. - If the company fails to meet the performance targets in any given year, the corresponding restricted stocks and stock options for that year will not vest or be exercisable, and will be forfeited [6][10]. Group 3: Decision-Making Process - The plan underwent a thorough decision-making process, including multiple board meetings and approvals from the remuneration and assessment committee, ensuring compliance with relevant laws and regulations [11][13][22]. - The company conducted a self-examination regarding insider trading by participants in the incentive plan, confirming no violations occurred in the six months prior to the grant date [24]. Group 4: Financial Implications - The funds raised through this incentive plan will be used to supplement the company's working capital [25]. - The company anticipates that the costs associated with the incentive plan will have a minor impact on net profits, while the potential positive effects on performance and management motivation are expected to outweigh these costs [30].